Potent type III phosphodiesterase (PDE3) inhibitor (IC50
= 36 nM). Inhibits platelet aggregation and produces potent thrombocytopenic effects via inhibition of megakaryocyte maturation.
Soluble to 10 mM in DMSO
Desiccate at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.
Mazur et al.
Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
Wang et al.